Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of therapies for metabolic dysfunction associated steatohepatitis (MASH), a progressive liver disease that can lead to cirrhosis and liver failure. The company's lead product, Rezdiffra (resmetirom), is an oral, once daily thyroid hormone receptor beta agonist approved in the United States and Europe for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis. Beyond Rezdiffra, Madrigal is building a broad pipeline that includes MGL 2086, an oral glucagon like peptide 1 receptor agonist from CSPC Pharmaceuticals; ervogastat, a diacylglycerol O acyltransferase 2 inhibitor from Pfizer; and 6 small interfering RNA programs from Rocure targeting MASH related genes. The company does not own manufacturing facilities and relies on third party contract manufacturers for active pharmaceutical ingredient and finished drug supply.

The company generates revenue principally from the sale of Rezdiffra in the United States and Europe. In 2025, product sales of Rezdiffra amounted to $958.4 million, and quarterly sales were annualizing at more than $1.0 billion by year end. Madrigal secures reimbursement through contracts with commercial insurers and government payers, and distributes the product via specialty pharmacy networks that dispense the medication to patients prescribed by hepatologists, gastroenterologists and endocrinologists. While the company does not currently receive royalties or milestone payments from its licensed pipeline candidates, future commercial success of those programs could provide additional revenue streams. Manufacturing is outsourced to established contract manufacturing organizations such as Evonik for active pharmaceutical ingredient and UPM and Corden for tablet formulation, ensuring a reliable supply chain for commercial demand.

Madrigal Pharmaceuticals occupies a pioneering niche in the MASH treatment arena as the first company to obtain approval for a therapy from both the U. S. Food and Drug Administration and the European Commission for noncirrhotic MASH with moderate to advanced fibrosis. Epidemiology estimates indicate approximately 315,000 diagnosed patients in the United States and around 370,000 in Europe who have MASH with F2 to F3 fibrosis and are under specialist care, representing a sizable addressable market expected to grow as awareness and diagnostic rates improve. Competitors include Novo Nordisk advancing semaglutide for MASH, Inventiva with lanifibranor, Roche with saroglitazar, Eli Lilly with various tirzepatide related programs, and Boehringer Ingelheim exploring endothelin receptor antagonists and other novel mechanisms. Numerous preclinical and clinical programs investigate PPAR agonists, GLP1/glucose dependent polypeptide dual agonists, fibroblast growth factor 21 agonists, farnesoid X receptor modulators and other emerging classes. Madrigal’s competitive edge stems from its first mover advantage, a liver directed mechanism targeting hepatic thyroid hormone receptor beta, and a robust patent portfolio protecting Rezdiffra’s composition of matter and weight based dosing regimen until 2045, providing a lengthy market exclusivity period. The company’s pipeline of complementary agents such as MGL 2086, ervogastat and siRNA molecules aims to enhance efficacy across the broader MASH spectrum and to address patient subsets that may not respond adequately to monotherapy.

The company’s customers are patients living with MASH who receive care from hepatologists, gastroenterologists and endocrinologists, specialists who identify and treat the disease. Madrigal engages these physicians through a field force that provides education on the natural history of MASH, the clinical benefits of Rezdiffra and appropriate prescribing practices. In the United States, the product is distributed via specialty pharmacy networks that deliver the medication directly to patients’ homes or to specialty clinics, while in Europe the company launched in Germany and plans to expand country by country as reimbursement approvals are secured. Payors, including private health insurers and government programs such as Medicare and Medicaid, are customers because they determine coverage and reimbursement levels that affect patient access. To support affordability, Madrigal offers patient assistance programs and co pay coupons for eligible individuals, although availability varies by jurisdiction. Overall, the company’s commercial success depends on reaching the diagnosed patient population, securing favorable payer contracts and maintaining a reliable supply chain via its third party manufacturers.